Email updates

Keep up to date with the latest news and content from BMC Cancer and BioMed Central.

Open Access Research article

Serial detection of circulating tumour cells by reverse transcriptase-polymerase chain reaction assays is a marker for poor outcome in patients with malignant melanoma

Giuseppe Palmieri1*, Sabrina MR Satriano2, Mario Budroni3, Antonio Cossu4, Francesco Tanda4, Sergio Canzanella5, Corrado Caracò2, Ester Simeone2, Antonio Daponte2, Nicola Mozzillo2, Giuseppe Comella2, Giuseppe Castello2 and Paolo A Ascierto2

Author Affiliations

1 Istituto di Chimica Biomolecolare-Consiglio Nazionale Ricerche, Li Punti-Sassari, Italy

2 Istituto Nazionale Tumori "Fondazione Pascale", Napoli, Italy

3 Centro Multizonale di Osservazione Epidemiologica, Azienda U.S.L. 1, Sassari, Italy

4 Servizio di Anatomia Patologica, Azienda U.S.L. 1, Sassari, Italy

5 Associazione House Hospital Onlus, Napoli, Italy

For all author emails, please log on.

BMC Cancer 2006, 6:266  doi:10.1186/1471-2407-6-266

Published: 15 November 2006



Detection of circulating malignant cells (CMCs) through a reverse transcriptase-polymerase chain reaction (RT-PCR) assay seems to be a demonstration of systemic disease. We here evaluated the prognostic role of RT-PCR assays in serially-taken peripheral blood samples from patients with malignant melanoma (MM).


One hundred forty-nine melanoma patients with disease stage ranging from I to III were consecutively collected in 1997. A multi-marker RT-PCR assay was used on peripheral blood samples obtained at time of diagnosis and every 6 months during the first two years of follow-up (total: 5 samples). Univariate and multivariate analyses were performed after 83 months of median follow-up.


Detection of at least one circulating mRNA marker was considered a signal of the presence of CMC (referred to as PCR-positive assay). A significant correlation was found between the rate of recurrences and the increasing number of PCR-positive assays (P = 0.007). Presence of CMC in a high number (≥2) of analysed blood samples was significantly correlated with a poor clinical outcome (disease-free survival: P = 0.019; overall survival: P = 0.034). Multivariate analysis revealed that presence of a PCR-positive status does play a role as independent prognostic factors for overall survival in melanoma patients, adding precision to the predictive power of the disease stage.


Our findings indicated that serial RT-PCR assay may identify a high risk subset of melanoma patients with occult cancer cells constantly detected in blood circulation. Prolonged presence of CMCs seems to act as a surrogate marker of disease progression or a sign of more aggressive disease.